<i>TP53</i> Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 34127506.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1750.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with chronic lymphocytic leukemia carrying a single <i>TP53</i> hit (chromosome 17p deletion or single <i>TP53</i> mutation) demonstrate excellent progression-free survival and overall survival on ibrutinib compared with cases harboring multiple <i>TP53</i> hits. Testing <i>TP53</i> deletion/mutation combining FISH and deep next-generation sequencing should be performed for a correct patient evaluation.<i>See related article by Brieghel et al., p. 4531</i>.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell